港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

醫美概念股

1,052.864

-27.807-2.57%

漲家數：- -

跌家數：11

平家數：2

市盈率：- -

高：1,097.798

開：1,080.672

低：1,046.950

收：1,080.672

成交量：4,704.44萬

成交額：5.83億

市值：1,743.26億

流通市值：1,302.51億

資料載入中...

總覽新聞資訊

現代牙科(03600)採納股份獎勵計劃

現代牙科(03600)發布年度業績，股東應占溢利5.97億港元按年增加46.32%

四環醫藥(00460)出現大手買入130萬股，成交價$1.28，涉資166.4萬

阿斯达克财经

【券商聚焦】中信建投：醫療器械板塊拐點來臨，26年業績改善個股存在業績估值修復機會

復星醫藥2025年報：收入417億，淨利增速21.7%，創新藥與境外收入佔比同步提升

四環醫藥(00460)出現大手買入130萬股，成交價$1.32，涉資171.6萬

阿斯达克财经

復星醫藥盤中升逾5% 去年純利按年增長21.69%至33.71億元

復星醫藥(02196)擬派發末期股息每股0.39元

麗豐控股(01125)公布中期業績公司擁有人應占淨虧損3.84億港元按年增長1.34倍

復星醫藥(02196)控股子公司擬新增開展融資租賃業務

復星醫藥：關於2026年續聘會計師事務所的公告

中國復星醫藥去年淨利按年增超兩成，創新藥收入與境外收入佔比均提升

復星醫藥(02196)發布2025年報：創新藥和全球化雙引擎驅動高質量發展

軒竹生物-B(02575)漲逾8% 安久衞治療反流性食管炎III期試驗完成全部受試者入組

【券商聚焦】中信證券：GDF-15阻斷劑有望在未來獲批治療腫瘤惡病質

《業績》復鋭醫療科技(01696.HK)全年純利1,902萬美元跌24.3% 末期息派9.5港仙

阿斯达克财经

復鋭醫療科技2025年業績實現穩健增長

復鋭醫療科技(01696)發布年度業績股東應占溢利1901.6萬美元按年減少24.32%

昊海生物科技(06826)3月23日耗資約240.55萬港元回購10.72萬股

四環醫藥(00460)出現大手賣出120萬股，成交價$1.27，涉資152.4萬

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1593/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":1052.8644,"timestamp":1774512495612,"preClose":1080.6718,"halted":0,"volume":47044383,"delay":0,"changeRate":-0.025732,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-27.807373,"latestTime":"03-26 16:00:00","open":1080.6718,"high":1097.7981,"low":1046.9497,"amount":582544096,"amplitude":0.047053,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":1.554461,"peRate":23.844152,"turnoverRate":0.002285,"increases":0,"decrements":11,"flats":2,"marketCap":174326077576,"floatMarketCap":130251360456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1097.7981,"amplitude":0.047053,"preClose":1080.6718,"low":1046.9497,"pbRate":"1.554461","latestPrice":1052.8644,"volume":47044383,"delay":0,"open":1080.6718,"prevYearClose":1094.978,"prevWeekClose":1084.158,"prevMonthClose":1133.252,"prevQuarterClose":1094.978,"fiveDayClose":1101.872,"twentyDayClose":1118.873,"sixtyDayClose":1143.453,"secType":"PLATE","market":"HK","turnoverRate":0.002285,"peRate":23.844152,"marketCap":174326077576,"floatMarketCap":130251360456,"timestamp":1774512495612,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":0,"down":11,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622481861","title":"現代牙科(03600)採納股份獎勵計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2622481861","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622481861?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 23:11","pubTimestamp":1774537867,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代牙科(03600)公布，公司已于2026年3月26日采纳股份奖励计划。根据股份奖励计划可授出的股份最高数目不得超过于采纳日期的已发行股份总数(不包括库存股份，(如有))的百分之十(10%)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1593","BK0251","301122","03600","BK1583"],"gpt_icon":0},{"id":"2622861948","title":"現代牙科(03600)發布年度業績，股東應占溢利5.97億港元 按年增加46.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622861948","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622861948?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 23:06","pubTimestamp":1774537604,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代牙科 发布截至2025年12月31日止年度业绩，该集团取得收益37.37亿港元，同比增加11.07%;公司拥有人应占溢利5.97亿港元，同比增加46.32%;每股盈利63.7港仙，拟派发末期股息每股普通股15.0港仙。截至2025年12月31日止年度，在牙科行业数码化趋势持续的支持下，本集团的多维度策略及持续提升的营运效率及生产力，使其于本期间的收益、纯利及EBITDA 数字均创下纪录新高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1100","BK1583","03600"],"gpt_icon":0},{"id":"2622329938","title":"四環醫藥(00460)出現大手買入130萬股，成交價$1.28，涉資166.4萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2622329938","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622329938?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 15:50","pubTimestamp":1774511400,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午03:50出现大手买入，成交量为130万，成交价为港币$1.28，涉资166.4万。至目前为止，股价跌3.03%，今日最高价为$1.34，而最低价为$1.28，总成交量为1.774千万股，总成交金额港币$2.306千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603266608/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603266608/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1593","BK1515","BK1600","00460"],"gpt_icon":0},{"id":"2622818008","title":"【券商聚焦】中信建投：醫療器械板塊拐點來臨，26年業績改善個股存在業績估值修復機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2622818008","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622818008?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:18","pubTimestamp":1774487918,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会。建议持续关注市场空间大、国产化率低的创新器械赛道，以及并购重组、脑机接口、AI医疗、手术机器人、外骨骼机器人等主题方向的投资机会。潜在催化较多的方向有望出现涨幅数倍的个股，未来AI医疗、脑机接口等也有望成为投资人重点关注的新科技方向。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977292","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826","BK1593","BK1574","601066","BK1571","BK1591","09997","BK1584","BK1502","BK1583","LU0173614495.USD","159883","01066","01302","BK1615","BK1142","BK1100","09996","BK1610","BK1600","02190","BK1222","02235","BK1515","BK1589","BK1585","BK1617","LU0287142896.SGD","BK1247","02252","BK1587","BK1501","BK1189","00853","BK1161","00241","BK0276"],"gpt_icon":0},{"id":"2622074818","title":"復星醫藥2025年報：收入417億，淨利增速21.7%，創新藥與境外收入佔比同步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074818","media":"IPO早知道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074818?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 21:32","pubTimestamp":1774445520,"startTime":"0","endTime":"0","summary":"报告期内，经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，增长主要系对外授权收入增加所致。创新药管线：研发投入转向商业兑现的效率提升复星医药2025年研发总投入达59.13亿元，同比增长6.46%，其中创新药品相关研发投入43.03亿元，同比大增15.98%，占研发总投入的72.77%，占比同比提升5.97个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-25/doc-inhsfmmn0790711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0012","02196","BK0175","BK0187","BK1515","BK1574","600196","BK0183","BK0060","BK0096","06978","BK0239","BK0188","BK0028","159992","BK1191","BK0196","BK1161","BK1593"],"gpt_icon":0},{"id":"2622236460","title":"四環醫藥(00460)出現大手買入130萬股，成交價$1.32，涉資171.6萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2622236460","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622236460?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 15:40","pubTimestamp":1774424400,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午03:40出现大手买入，成交量为130万，成交价为港币$1.32，涉资171.6万。至目前为止，股价无升跌，今日最高价为$1.34，而最低价为$1.3，总成交量为2.808千万股，总成交金额港币$3.707千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603258254/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603258254/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1600","00460","BK1593","BK1515"],"gpt_icon":0},{"id":"2622845045","title":"復星醫藥盤中升逾5% 去年純利按年增長21.69%至33.71億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845045","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622845045?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 10:54","pubTimestamp":1774407240,"startTime":"0","endTime":"0","summary":"　　复星医药盘中涨超5%，截至发稿，股价上涨3.84%，现报18.93港元，成交额2494.07万港元。　　3月24日晚，复星医药发布2025年度业绩，该集团取得营业收入人民币416.62亿元，同比增加1.45%；归属于上市公司股东的净利润33.71亿元，同比增加21.69%；基本每股收益1.27元，拟每10股派发现金红利3.90元（税前）。　　报告期内，集团创新药品实现收入98.93亿元，同比增长29.59%，占制药业务收入比重提升至33.16%，较上年提高6.77个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-25/doc-inhseiye3701176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","600196","BK0175","BK1593","BK1515","BK0183","BK0188","02196","BK0012","BK0096","BK0239","BK1191","BK0196","BK0028","BK0060"],"gpt_icon":0},{"id":"2622401171","title":"復星醫藥(02196)擬派發末期股息每股0.39元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622401171","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622401171?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 07:34","pubTimestamp":1774395268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司拟派发末期股息每股0.39元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK0175","BK0188","BK4585","VIG","BK0187","BK1515","BK0012","BK0028","02196","BK0060","BK0096","BK1191","BK1593","BK4588","BK0239","BK0183","BK0196"],"gpt_icon":0},{"id":"2621093847","title":"麗豐控股(01125)公布中期業績 公司擁有人應占淨虧損3.84億港元 按年增長1.34倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2621093847","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621093847?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 22:12","pubTimestamp":1774361556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽丰控股(01125)公布截至2026年1月31日止6个月中期业绩，营业额约9.27亿港元，同比增长43.1%;公司拥有人应占净亏损3.84亿港元，同比增长1.34倍;每股亏损1.16港元。公告称，亏损增长主要由于于回顾期间内出售横琴创新方第二期的一幢住房大楼(T1)及撇减横琴创新方第二期的物业(主要为T3)而产生的亏损。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"丽丰控股(01125)公布中期业绩 公司拥有人应占净亏损3.84亿港元 同比增长1.34倍","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","01125","BK1240"],"gpt_icon":0},{"id":"2621067566","title":"復星醫藥(02196)控股子公司擬新增開展融資租賃業務","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067566?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:53","pubTimestamp":1774356801,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，为进一步拓宽融资渠道，公司部分控股子公司拟与具备相应资质的融资租赁公司/金融租赁公司新增开展融资租赁业务，融资总额不超过人民币6.5亿元，包括：(1)以部分自有资产设备作为转让标的及租赁物开展售后回租、(2)以新购资产设备直租。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0196","BK1191","BK1593","BK0060","BK0096","BK0239","BK0012","02196","BK0175","BK1515","BK0028","BK0187","BK0183","600196"],"gpt_icon":0},{"id":"2621757062","title":"復星醫藥：關於2026年續聘會計師事務所的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757062","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621757062?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:25","pubTimestamp":1774355100,"startTime":"0","endTime":"0","summary":"证券日报网讯3月24日，复星医药发布公告称，2026年3月24日，公司第十届董事会第二十五次会议审议通过了关于本公司2026年续聘会计师事务所及2025年会计师事务所报酬的议案，拟续聘安永华明会计师事务所（特殊普通合伙）为本公司2026年度境内财务报告和内部控制审计机构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682800769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0060","BK0175","BK1593","BK1191","BK0196","600196","BK0028","02196","BK0187","BK0096","BK0012","BK0239","BK0188","BK1515"],"gpt_icon":0},{"id":"2621162069","title":"中國復星醫藥去年淨利按年增超兩成，創新藥收入與境外收入佔比均提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2621162069","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621162069?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 19:21","pubTimestamp":1774351293,"startTime":"0","endTime":"0","summary":"路透北京3月24日 - 中国“复星系”医药及疫苗巨头--复星医药600196.SS2196.HK周二公布，去年营收同比微升，净利润则大增逾两成；公司称创新驱动与国际化成效逐步显现，创新药品收入占比与境外收入占比的同步提升。复星医药发布在上交所的财报称，2025年创新药品收入占制药业务收入比重、境外业务收入占营业收入比重双双提升至30%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL4T40C097:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0239","BK1191","600196","BK1593","BK0060","00656","BK0175","02196","BK0187","BK0096","BK0012","BK0196","BK1515","BK0183","BK0188","BK1230"],"gpt_icon":0},{"id":"2621069488","title":"復星醫藥(02196)發布2025年報：創新藥和全球化雙引擎驅動高質量發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069488","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069488?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 19:16","pubTimestamp":1774350963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复星医药(600196.SH，02196)公布2025年度经营业绩。复星医药以创新研发突破与全球化体系升级为双引擎，实现营业收入人民币416.62亿元，同比增长1.45%，其中，创新药品收入98.93亿元，同比增长29.59%;境外收入129.77亿元，同比增长14.87%，两大核心指标实现双增长，深化复星医药高质量发展的底层逻辑。归母净利润33.71亿元，同比增长21.69%;归母扣非净利润23.40亿元，同比增长1.12%;经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，高质量发展底座进一步夯实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0187","BK1515","BK0060","BK0183","BK0028","BK1191","159992","BK0012","BK0175","BK0239","BK0096","06978","600196","02196","BK1161","BK1593","BK0188","BK1574"],"gpt_icon":0},{"id":"2621603174","title":"軒竹生物-B(02575)漲逾8% 安久衞治療反流性食管炎III期試驗完成全部受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2621603174","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621603174?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 10:10","pubTimestamp":1774318245,"startTime":"0","endTime":"0","summary":"消息面上，四环医药发布公告，公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。据悉，安奈拉唑钠肠溶片于2023年6月获得中国国家药品监督管理局批准上市，用于患者治疗十二指肠溃疡。此次III期临床研究于2025年7月全面展开，近期完成受试者入组，标志着本公司在创新药物研发方面取得了重要进展。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977089","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","02575","BK1600","BK1191","00460","III","BK4134"],"gpt_icon":0},{"id":"2621052036","title":"【券商聚焦】中信證券：GDF-15阻斷劑有望在未來獲批治療腫瘤惡病質","url":"https://stock-news.laohu8.com/highlight/detail?id=2621052036","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621052036?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:01","pubTimestamp":1774314061,"startTime":"0","endTime":"0","summary":"目前GDF-15阻断剂行业处于临床开发阶段，尚无任何药物获批，多数临床管线处于早期阶段，进度最快的为辉瑞公司和CatalYm公司。鉴于Ponsegromab在II期临床试验中的优异结果以及Ponsegromab的II/III期临床试验设计，该机构认为其有望获批治疗肿瘤恶病质，成为GDF-15阻断剂上市后第一个适应症。后续如果Ponsegromab成功上市以及Visugromab读出积极数据，将催化GDF-15阻断剂市场快速增长。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IE00B543WZ88.USD","BK1585","LU0348783233.USD","01099","06030","LU0307460666.USD","02367","HK0000165453.HKD","LU1580142542.USD","BK1564","02196","LU1781817850.SGD","SG9999014674.SGD","600030","BK1141","BK0276","03933","02268","09926","LU2328871848.SGD","BK0012","BK0028","06821","LU0417516902.SGD","LU1655091616.SGD","LU1997245094.SGD","LU1328615791.USD","LU0405327148.USD","IE00BPRC5H50.USD","LU0640798160.USD","06160","02228","09688","BK1207","BK1574","LU1303224171.USD","LU2289578879.USD","01530","LU1064131003.USD","01789","BK1191","LU1255011170.USD","LU0405327494.USD","BK1515","BK1593","LU1794554557.SGD","LU0348735423.USD","BK1147","LU0348825331.USD"],"gpt_icon":0},{"id":"2621088538","title":"《業績》復鋭醫療科技(01696.HK)全年純利1,902萬美元跌24.3%  末期息派9.5港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2621088538","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621088538?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 00:44","pubTimestamp":1774284240,"startTime":"0","endTime":"0","summary":"复锐医疗科技(01696.HK) 公布2025年度业绩，收益3.65亿美元，按年增加4.7%。录得纯利1,902万美元，倒退24.3%，每股盈利4.06美仙。末期息派9.5港仙。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2025/08/20中期业绩无派息2025/03/19末期业绩股息：港元 0.12602024/08/21中期业绩无派息2024/03/20末期业绩股息：港元 0.1580AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190704152928340_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190704152928340_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511622/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511622/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1100","BK1593","01696","BK1585"],"gpt_icon":0},{"id":"2621744085","title":"復鋭醫療科技2025年業績實現穩健增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744085","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744085?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277700,"startTime":"0","endTime":"0","summary":"注射填充业务收入为28.0百万美元，较2024年同比增长185.6%。经调整净利润为31.0百万美元，较2024年的28.7百万美元同比增长7.9%。经调整净利润率为8.5%，2024年同期为8.2%。\" 复锐医疗科技首席执行官Eyal Ben David先生表示：\"2025年是复锐医疗科技夯实下一阶段增长根基的关键之年。\" 复锐医疗科技联席首席执行官兼首席财务官李家宏先生表示：\"2025年，复锐医疗科技积极应对外部挑战，有序推进各项战略部署，财务表现稳健向好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4916393_ZH16393_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1593","BK1585","BK1100","01696"],"gpt_icon":0},{"id":"2621896702","title":"復鋭醫療科技(01696)發布年度業績 股東應占溢利1901.6萬美元 按年減少24.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621896702","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621896702?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 22:38","pubTimestamp":1774276690,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复锐医疗科技(01696)发布截至2025年12月31日止年度业绩，该集团期内取得收益3.65亿美元，同比增加4.7%;母公司拥有人应占溢利1901.6万美元，同比减少24.32%;每股基本盈利4.06美仙;拟派发末期股息每股0.095港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1585","BK1593","01696"],"gpt_icon":0},{"id":"2621501771","title":"昊海生物科技(06826)3月23日耗資約240.55萬港元回購10.72萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621501771","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621501771?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 17:32","pubTimestamp":1774258365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)公布，2026年3月23日耗资约240.55万港元回购10.72万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","BK1161","BK1593"],"gpt_icon":0},{"id":"2621172068","title":"四環醫藥(00460)出現大手賣出120萬股，成交價$1.27，涉資152.4萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2621172068","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621172068?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 14:55","pubTimestamp":1774248900,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午02:55出现大手卖出，成交量为120万，成交价为港币$1.27，涉资152.4万。至目前为止，股价跌7.971%，今日最高价为$1.38，而最低价为$1.27，总成交量为2.646千万股，总成交金额港币$3.447千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603239487/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603239487/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1593","BK1515","BK1600","BK1191","00460"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}]}}